97 related articles for article (PubMed ID: 24565899)
21. In vitro-in vivo correlation for nevirapine extended release tablets.
Macha S; Yong CL; Darrington T; Davis MS; MacGregor TR; Castles M; Krill SL
Biopharm Drug Dispos; 2009 Dec; 30(9):542-50. PubMed ID: 19876936
[TBL] [Abstract][Full Text] [Related]
22. Extended release dosage form of glipizide: development and validation of a level A in vitro-in vivo correlation.
Ghosh A; Bhaumik UK; Bose A; Mandal U; Gowda V; Chatterjee B; Chakrabarty US; Pal TK
Biol Pharm Bull; 2008 Oct; 31(10):1946-51. PubMed ID: 18827360
[TBL] [Abstract][Full Text] [Related]
23. Formulation variation and in vitro-in vivo correlation for a rapidly swellable three-layered tablet of tamsulosin HCl.
Park JS; Shim JY; Park JS; Lee MJ; Kang JM; Lee SH; Kwon MC; Choi YW; Jeong SH
Chem Pharm Bull (Tokyo); 2011; 59(5):529-35. PubMed ID: 21532187
[TBL] [Abstract][Full Text] [Related]
24. Suitability of a minipig model in assessing clinical bioperformance of matrix and multiparticulate extended-release formulations for a BCS class III Drug development candidate.
Kesisoglou F; Xie IH; Manser K; Wu Y; Hardy I; Fitzpatrick S
J Pharm Sci; 2014 Feb; 103(2):636-42. PubMed ID: 24382706
[TBL] [Abstract][Full Text] [Related]
25. Assessment of xanthan gum based sustained release matrix tablets containing highly water-soluble propranolol HCl.
Ali A; Iqbal M; Akhtar N; Khan HM; Ullah A; Uddin M; Khan MT
Acta Pol Pharm; 2013; 70(2):283-9. PubMed ID: 23614284
[TBL] [Abstract][Full Text] [Related]
26. Development of In Vitro-In Vivo Correlation for Potassium Chloride Extended Release Tablet Formulation Using Urinary Pharmacokinetic Data.
Mittapalli RK; Marroum P; Qiu Y; Apfelbaum K; Xiong H
Pharm Res; 2017 Jul; 34(7):1527-1533. PubMed ID: 28512718
[TBL] [Abstract][Full Text] [Related]
27. A time-scaled convolution approach to construct IVIVC for enteric-coated acetylsalicylic acid tablets.
Al-Gousous J; Langguth P
Pharmazie; 2018 Feb; 73(2):67-69. PubMed ID: 29442006
[TBL] [Abstract][Full Text] [Related]
28. Development of in vitro-in vivo correlation for extended-release niacin after administration of hypromellose-based matrix formulations to healthy volunteers.
Kesisoglou F; Rossenu S; Farrell C; Van Den Heuvel M; Prohn M; Fitzpatrick S; De Kam PJ; Vargo R
J Pharm Sci; 2014 Nov; 103(11):3713-3723. PubMed ID: 25256703
[TBL] [Abstract][Full Text] [Related]
29. Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets.
Takka S; Sakr A; Goldberg A
J Control Release; 2003 Feb; 88(1):147-57. PubMed ID: 12586512
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of in vitro release rate and in vivo absorption characteristics of four metoprolol tartrate immediate-release tablet formulations.
Rekhi GS; Eddington ND; Fossler MJ; Schwartz P; Lesko LJ; Augsburger LL
Pharm Dev Technol; 1997 Feb; 2(1):11-24. PubMed ID: 9552427
[TBL] [Abstract][Full Text] [Related]
31. In vitro-in vivo correlation of modified release dosage form of lamotrigine.
Shah HJ; Subbaiah G; Patel DM; Patel CN
Biopharm Drug Dispos; 2009 Dec; 30(9):524-31. PubMed ID: 19823969
[TBL] [Abstract][Full Text] [Related]
32. In vitro-in vivo correlation and bioavailability studies of captopril from novel controlled release donut shaped tablet.
Mandal AS; Chatterjee S; Kundu S; Biswas N; Guha A; Paul S; Kuotsu K
Int J Pharm; 2011 Dec; 421(1):145-50. PubMed ID: 21945741
[TBL] [Abstract][Full Text] [Related]
33. A novel pulsatile drug delivery system based on the physiochemical reaction between acrylic copolymer and organic acid: in vitro and in vivo evaluation.
Zhang Z; Qi X; Li X; Xing J; Zhu X; Wu Z
Int J Pharm; 2014 Feb; 462(1-2):66-73. PubMed ID: 24368107
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
Jenner P; Könen-Bergmann M; Schepers C; Haertter S
Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
[TBL] [Abstract][Full Text] [Related]
35. Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets.
Mettu SR; Veerareddy PR
Drug Res (Stuttg); 2013 Nov; 63(11):586-90. PubMed ID: 23780501
[TBL] [Abstract][Full Text] [Related]
36. Dependence of in vitro-in vivo correlation analysis acceptability on model selections.
Polli JE
Pharm Dev Technol; 1999 Jan; 4(1):89-96. PubMed ID: 10027217
[TBL] [Abstract][Full Text] [Related]
37. In vivo and in vitro evaluation of three controlled release principles of 6-N-cyclohexyl-2'-O-methyladenosine.
Royce A; Li S; Weaver M; Shah U
J Control Release; 2004 May; 97(1):79-90. PubMed ID: 15147806
[TBL] [Abstract][Full Text] [Related]
38. Chronotherapeutically Modulated Pulsatile System of Valsartan Nanocrystals-an In Vitro and In Vivo Evaluation.
Biswas N; Kuotsu K
AAPS PharmSciTech; 2017 Feb; 18(2):349-357. PubMed ID: 26961969
[TBL] [Abstract][Full Text] [Related]
39. Validated in vitro/in vivo correlation of prolonged-release oxycodone/naloxone with differing dissolution rates in relation to gastrointestinal transit times.
Mundin GE; Smith KJ; Mysicka J; Heun G; Krämer M; Hahn U; Leuner C
Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1495-503. PubMed ID: 23025349
[TBL] [Abstract][Full Text] [Related]
40. An investigation into the usefulness of generalized regression neural network analysis in the development of level A in vitro-in vivo correlation.
Parojcić J; Ibrić S; Djurić Z; Jovanović M; Corrigan OI
Eur J Pharm Sci; 2007 Mar; 30(3-4):264-72. PubMed ID: 17188851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
